placenta-derived multipotent mesenchymal stromal cells

**Placenta-derived multipotent mesenchymal stromal cells (P-MSCs)** are multipotent stem cells isolated from human placenta tissue, exhibiting high proliferative capacity, low immunogenicity, and immune-privileged properties due to their origin in the feto-maternal interface. They exert therapeutic effects primarily through paracrine secretion of immunomodulatory cytokines, chemokines, and growth factors, suppressing pro-inflammatory responses (e.g., via IDO, HLA-G, IL-10), promoting T-regulatory cells, inhibiting T-cell proliferation, and facilitating tissue repair, angiogenesis, and regeneration without tumorigenic potential. P-MSCs show advantages over bone marrow-derived MSCs, including easier procurement from discarded placental tissue, higher yield, and resistance to certain infections like SARS-CoV-2; they have been investigated in clinical trials for conditions like COVID-19-associated ARDS, graft-versus-host disease, neurological disorders, and joint diseases, often administered intravenously or intramuscularly at doses around 100-200 million cells per patient.[1][2][3][6]

Other names

placenta-derived mesenchymal stem cellsP-MSCsplacenta-derived MSCs